Attached files
file | filename |
---|---|
EX-99.2 - PRESS RELEASE DATED NOVEMBER 2, 2016 - H-CYTE, INC. | ex-glp.htm |
EX-99.1 - PRESS RELEASE DATED NOVEMBER 1, 2016 - H-CYTE, INC. | ex-nasdaqext.htm |
8-K - PRIMARY DOCUMENT - H-CYTE, INC. | mdvx8k_nov2016.htm |
Exhibit 99.3
Medovex Corporation Conducts Successful Cadaver Lab at NASS
2016
ATLANTA, GA--(Marketwired – November
3, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology
products, today announced that the Company held a successful
cadaver lab during NASS 2016.
Thousands of spine clinicians gathered at
the Boston Convention and Exhibition center for the Annual North
American Spine Society in Boston, MA from October
26th
to 28th,
2016. The conference and exhibition provided a perfect setting for
an outstanding agenda with specialty surgical labs to highlight the
innovative DenerveX™ System, a minimally invasive surgical (MIS)
procedure pioneered by Medovex. The DenerveX System was built
around the combination of denervation and capsulectomy with
reproducible results, a potential paradigm shift in the treatment
of Facet Joint pain.
As part of the
product exhibition, Medovex held a successful cadaver lab lead by
their medical advisory board members Martin Deeg, MD from
Stuttgart, Germany, Vik Kapoor, MD from Manchester, England, as
well as Gabriel Davila, MD from Columbia, Latin America,
highlighting its innovative DenerveX System. Thirty spine surgeons
from Europe and Latin America attended the lab and experienced and
used the DenerveX System. The DenerveX treatment modality,
uses Rotablation™ technology, high heat and rotational
capsular tissue shaving, in a minimally invasive posterior
capsulectomy procedure.
Medovex’s presence at NASS is an
extension of the Company’s continued investment in its
strategic expansion throughout the Europe,
Middle East and Africa (EMEA) market and other important markets
throughout the World. NASS experienced strong growth regarding
members, activities and participants at annual meetings and
participants from all over the world.
Manfred Sablowski, Senior Vice President of
Global Sales & Marketing for Medovex said, “Events such
as NASS are important to our worldwide expansion efforts and
represent the ideal venue to leverage our future market development
taking our well planned strategy across the entire EMEA region.
Medovex is well-positioned to drive customer adoption of our new
innovative DenerveX™ System across
Europe.”
Sablowski
continued, “Opportunities like the cadaver lab at NASS are
important milestones for Medovex, as well as a key inflection point
for our Company’s strategy to grow our business in EMEA.
Importantly, it provides potential future customers the opportunity
to experience firsthand the easy to use DenerveX
System”.
The DenerveX
System consists of the DenerveX device, a single use medical device
and the DenerveX Pro-40 Power Generator, both designed to be less
invasive with faster recovery time than current surgical treatment
options. It consists of two procedures combined into one device and
is expected to provide for a longer lasting treatment solution
while offering potential savings to the health care system.
DenerveX is not yet commercially available.
DenerveX
system is not yet CE marked or FDA cleared and is not yet
commercially available.
About Medovex
Medovex was formed to acquire and develop a
diversified portfolio of potentially ground breaking medical
technology products. Criteria for selection include those products
with potential for significant improvement in the quality of
patient care combined with cost effectiveness. The Company's first
pipeline product, the DenerveX device, is intended to provide long
lasting relief from pain associated with facet joint syndrome at
significantly less cost than currently available options. To learn
more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement
Certain
statements in this press release constitute "forward-looking
statements" within the meaning of the federal securities laws.
Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "predict,"
"forecast," "project," "plan," "intend" or similar expressions, or
statements regarding intent, belief, or current expectations, are
forward-looking statements. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC"),
not limited to Risk Factors relating to its patent business
contained therein. Thus, actual results could be materially
different. The Company expressly disclaims any obligation to update
or alter statements whether as a result of new information, future
events or otherwise, except as required by law.
●
CONTACT
INFORMATION
Medovex
Corp.
Jason
Assad
470-505-9905
jassad@medovex.com